Financial Performance - Total revenue for the first quarter of 2023 was RMB 8.05 billion, an increase of 2.3% compared to RMB 7.87 billion in the same period of 2022[3]. - Shareholders' profit attributable to the company was RMB 1.43 billion, up 1.7% from RMB 1.40 billion in the same period of 2022[3]. - The gross profit for the same period was RMB 5,518,599 thousand, down from RMB 5,810,962 thousand in 2022, indicating a decrease of 5.0%[16]. - The company reported a net profit attributable to shareholders of RMB 1,428,843 thousand for the three months ended March 31, 2023, compared to RMB 1,404,519 thousand in 2022, reflecting a growth of 1.7%[14]. - The company recorded a net profit of RMB 258,075 thousand for the three months ended March 31, 2023, compared to RMB 238,994 thousand in the same period last year, reflecting an increase of approximately 7.99%[23]. - The company’s financial expenses amounted to RMB 4,429 thousand during the reporting period[20]. Revenue Breakdown - The revenue from the pharmaceutical business was RMB 6.42 billion, reflecting a 1.9% increase year-on-year, despite weak sales in anti-tumor products due to price reductions[4]. - The sales revenue from raw materials decreased by 4.6% to RMB 1.02 billion, primarily due to a decline in vitamin C sales[6]. - Revenue from functional foods and other products increased by 21.7% to RMB 615 million, driven by growth in caffeine products[7]. - The total sales from functional foods and other categories were RMB 681,788 thousand, showing a significant contribution to overall revenue[20]. - The sales of pharmaceutical products reached RMB 6,386,810 thousand, while raw material products generated RMB 551,046 thousand in revenue[20]. Research and Development - R&D expenses for the period were RMB 1.01 billion, an increase of 11.8%, accounting for 15.7% of pharmaceutical business revenue[9]. - Research and development expenses increased to RMB 1,007,649 thousand from RMB 901,517 thousand in the previous year, showing a rise of 11.8%[16]. - The company submitted 9 PCT international applications and received 16 patent grants, indicating ongoing innovation and intellectual property development[11]. Clinical Trials and Product Development - The company launched a new mRNA vaccine for COVID-19 in March 2023, which is now included in emergency use in China[8]. - In March 2023, the company completed the first patient dosing in a Phase III clinical trial for Donada (mitoxantrone hydrochloride liposome injection) for the treatment of platinum-resistant recurrent metastatic nasopharyngeal carcinoma[11]. - The company achieved the predefined endpoint in a Phase III trial for SYSA1903, a recombinant anti-IgE monoclonal antibody, for chronic spontaneous urticaria after H1 antihistamine treatment[11]. - The company initiated a randomized, double-blind, placebo-controlled Phase II/III clinical study for CM310 (IL-4Rα antibody) targeting moderate to severe asthma in March 2023[11]. - The company plans to continue developing new mRNA vaccines to address ongoing virus mutations and health threats[8]. Strategic Partnerships and Agreements - The company signed an exclusive licensing agreement with Corbus Pharmaceuticals, receiving an upfront payment of USD 7.5 million for the development and commercialization rights of SYS6002 (Nectin-4 ADC) in multiple regions[12]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]. Market Performance - Sales in the neurology segment increased by 9.8% to RMB 2.13 billion, while anti-tumor sales decreased by 33.1% to RMB 1.44 billion[5]. - The company reported a pre-tax profit of RMB 1,780,961 thousand for the three months ended March 31, 2023[20]. - Total revenue for the three months ended March 31, 2023, was RMB 8,208,384 thousand, a slight increase from RMB 7,967,163 thousand in the same period last year, representing a growth of approximately 3.02%[21]. - The gross profit for the same period was RMB 1,822,014 thousand, compared to RMB 1,873,870 thousand in the previous year, indicating a decrease of about 2.76%[21].
石药集团(01093) - 2023 Q1 - 季度业绩